Anika Therapeutics’ latest earnings call painted a cautiously optimistic picture, balancing clear commercial momentum and bottom-line progress against lingering revenue pressure, regulatory setbacks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results